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Abstract
Lysophosphatidic	acid	(LPA)	receptors	(nomenclature	as	agreed	by	the	NC-IUPHAR	Subcommittee	on
Lysophospholipid	Receptors	[54,	18,	80,	125])	are	activated	by	the	endogenous	phospholipid	LPA.	The	first
receptor,	LPA1,	was	identified	as	ventricular	zone	gene-1	(vzg-1)	[39],	leading	to	deorphanisation	of	members	of
the	endothelial	differentiation	gene	(edg)	family	as	other	LPA	receptors	along	with	sphingosine	1-phosphate
(S1P)	receptors.	Additional	LPA	receptor	GPCRs	were	later	identified.	Gene	names	have	been	codified	as
LPAR1,	etc.	to	reflect	the	receptor	function	of	proteins.	The	crystal	structure	of	LPA1	was	solved	and
demonstrates	extracellular	LPA	access	to	the	binding	pocket,	consistent	with	proposed	delivery	via	autotaxin
[12].	These	studies	have	also	implicated	cross-talk	with	endocannabinoids	via	phosphorylated	intermediates	that
can	also	activate	these	receptors.	The	identified	receptors	can	account	for	most,	although	not	all,	LPA-induced
phenomena	in	the	literature,	indicating	that	a	majority	of	LPA-dependent	phenomena	are	receptor-mediated.
Binding	affinities	of	unlabeled,	natural	LPA	and	AEAp	to	LPA1	were	measured	using	backscattering
interferometry	(pKd	=	9)	[81,	102].	Binding	affinities	were	77-fold	lower	than	than	values	obtained	using
radioactivity	[124].	Targeted	deletion	of	LPA	receptors	has	clarified	signalling	pathways	and	identified
physiological	and	pathophysiological	roles.	Independent	validation	by	multiple	groups	has	been	reported	in	the
peer-reviewed	literature	for	all	six	LPA	receptors	described	in	the	tables,	including	further	validation	using	a
distinct	read-out	via	a	novel	TGFα	"shedding"	assay	[47].	LPA	LPA	has	been	proposed	to	be	a	ligand	for
GPCR35	[92],	supported	by	a	recent	study	revealing	that	LPA	modulates	macrophage	function	through	GPR35
[53].	However	CXCL17	is	reported	to	be	a	ligand	for	GPR35/CXCR8	[74].	Moreover,	LPA	has	also	been
described	as	an	agonist	for	the	transient	receptor	potential	(Trp)	ion	channel	TRPV1	[85]	and	TRPA1	[57].	All	of
these	proposed	non-GPCR	receptor	identities	require	confirmation	and	are	not	currently	recognized	as	bona	fide
LPA	receptors.
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